Clinical Trial: Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study

Brief Summary: Recruitment of at least 10 adult patients (men and women) among individuals affected and admitted to the hospitals identified for the clinical study. All patients shall be between 18 and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's visits (day 1,3,7,10,14,21, and 28).

Detailed Summary:

Objective: primary objective Evaluation of the overall global clinical response based on secondary end points from 1 to 6 at the end of the therapy (Study day 14) and at the final visit at the end of the study - follow-up- (Study day 28) in comparison to the initial clinical state.

The evaluation will be based on: improvement/normalization in relation to the semi-quantitative scales at 3, 4 and 5 items or at opinion expressed as positive for at least 3 of the first 6 secondary end points.

secondary objectives

  1. Improvement on the basis of clinical symptoms;
  2. Antifungal efficacy from the cultures;
  3. Improvement on the basis of mycological blood testing;
  4. Improvement on the basis of laboratory diagnosis (hemogasanalysis, ESR, CPR);
  5. Improvement on the basis of radiological imaging (Rx, CAT HR,…);
  6. Improvement on the basis of endoscopic examination;
  7. Evaluate the plasma levels of SPK-843 after single dose and after multiple doses;
  8. Evaluate the safety in the administration of SPK-843.

Methodology: Open label multi center study


Sponsor: Proaparts srl

Current Primary Outcome: Evaluation of the overall global clinical response [ Time Frame: 28 days ]

Evaluation of the overall global clinical response based on secondary end points from 1 to 6 at the end of the therapy (Study day 14) and at the final visit at the end of the study - follow-up- (Study day 28) in comparison to the initial clinical state.


Original Primary Outcome: Same as current

Current Secondary Outcome: Evaluate the safety in the administration of SPK-843. [ Time Frame: 28 days ]

Original Secondary Outcome: Same as current

Information By: Proaparts srl

Dates:
Date Received: May 17, 2010
Date Started: May 2010
Date Completion: December 2011
Last Updated: June 6, 2011
Last Verified: June 2011